Reform the FDA citizen petition process to prevent it from being misused to delay approval of generic drugs and biosimilars.

Susan M. Collins · Maine · Republican

policy impact 0.70 specificity 0.82 extraction confidence 93%

Commitment kind: unknown. Promised action: not established. Promised outcome: not established. Deadline: unknown; not assumed expired.

Contest this claim

Occurrences

Senator Collins: I want to ask you about another reform that Senator Shaheen and I have been pushing, and it would reform the FDA citizen petition process.

Collins says she and Senator Shaheen are pushing a reform of the FDA citizen petition process to stop anti-competitive delays to generic and biosimilar approvals.

At HELP Hearing on Prescription Drug Aff... | U.S. Senator Susan Collins
primary · official_post · model gpt-5.4-mini

Evidence

legacy_unverified · Source version not recorded · locator unknown

Full Committee Hearing titled "From Regulator to Roadblock: How FDA Bureaucracy Stifles Innovation" was held on Thursday, February 26, 2026.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Recent Senate attention to FDA process barriers, but no direct evidence in the lookback window that Collins personally reformed the citizen-petition process.

unresolved same_term

From Regulator to Roadblock: How FDA Bureaucracy Stifles Innovation | Senate Committee On Aging
secondary · model gpt-5.4-mini · confidence 72%

Contest this evidence item

legacy_unverified · Source version not recorded · locator unknown

Axios reported that Sen. Susan Collins introduced a bill that would require biologic drug patents to be included on a list already maintained by the FDA.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Concrete later-term legislative action on a related drug-competition barrier, but it addressed patent listing rather than the FDA citizen-petition process itself.

partial later_term A for effort

Senate makes bipartisan strides toward drug patents
secondary · model gpt-5.4-mini · confidence 67%

Contest this evidence item

Assessments

Public state: unverified As of unknown · legacy_unverified · . Original AI recommendation (not independently established): partial. later_term

The available evidence does not show that Susan Collins achieved a reform of the FDA citizen-petition process itself. The 2026 Senate hearing reflects general attention to FDA barriers but not a delivered change by Collins on this specific mechanism. The 2019 bill on biologic patent listing addressed a related obstacle to generic and biosimilar competition, so it supports some credit for working on adjacent drug-approval delays, but it does not amount to fulfillment of the promised citizen-petition reform. Because the observed action is related but not the promised reform, partial credit fits better than full delivery or a documented serious failed attempt on the exact promise.

provider codex_cli · model gpt-5.4 · confidence 79%